This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Dental Stocks Poised to Perform Well in Second-Half 2021
by Trina Mukherjee
Let's keep a watch on three lucrative stocks, WST, HSIC and MMSI, in the dental space that investors can add to their watchlist backed by robust long-term prospects.
Masimo (MASI) Launches SuperSensor, Boosts Product Profile
by Zacks Equity Research
Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.
Glaukos (GKOS) Announces PMA Submission, Boosts iStent Platform
by Zacks Equity Research
Glaukos (GKOS) submits PMA application to the FDA, which can enhance the company's deep portfolio of novel glaucoma surgical devices and sustained pharmaceuticals.
Here's Why You Should Invest in Integer Holdings (ITGR) Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management.
LHC Group (LHCG) Closes Heart of Hospice Buyout, Expands Presence
by Zacks Equity Research
LHC Group (LHCG) expands its hospice presence in five states with the completion of Heart of Hospice buyout.
Masimo (MASI) Ties Up to Educate on Prescription Opioid Overuse
by Zacks Equity Research
Masimo (MASI) partners with Penington Institute to increase awareness on overdose from prescription opioids.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure raises a concern.
NextGen's (NXGN) Solutions to Boost Care for Homeless Community
by Zacks Equity Research
NextGen's (NXXGN) solutions collaborate with Neighborhood Health to provide care to Nashville's homeless community through the latter's street medicine program.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.
Masimo (MASI) Strengthens Global Footprint With New Launch
by Zacks Equity Research
Masimo's (MASI) western Europe launch of SafetyNet Alert not only expands its global presence but also aids in protecting patients taking opioids at home.
Merit Medical (MMSI) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Align Technology (ALGN) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Clear Aligners and Systems & CAD/CAM Services segments drove the top line for Align Technology (ALGN).
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business. However, high debt level remains a woe.
Masimo's (MASI) Noninvasive Continuous PVi Favored by New Study
by Zacks Equity Research
Masimo (MASI) reports study findings that will aid clinicians in getting meaningful information with respect to monitoring the volume status in critically ill patients with spontaneous breathing.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.
LabCorp (LH) Inks Deal to Assess Disparities in Drug Development
by Zacks Equity Research
LabCorp (LH) and CCORN partner to develop a patient registry and biobank to help design cancer clinical trials in diverse populations.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Merit Medical (MMSI) Expands Drainage Portfolio With New Product
by Zacks Equity Research
Merit Medical's (MMSI) new commercial product launch can make sample collection simple, safe and efficient.
Here's Why You Should Retain Glaukos (GKOS) Stock Right Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.
Cooper Companies (COO) Unit's MiSight Gets Approval in China
by Zacks Equity Research
CooperVision, a unit of Cooper Companies (COO), receives approval for MiSight 1 day contact lenses from China's National Medical Products Administration for use in China.
Here's Why You Should Retain Abiomed (ABMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
Merit Medical (MMSI) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Merit Medical (MMSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Merit Medical (MMSI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Merit Medical's (MMSI) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Merit Medical (MMSI), in the second quarter, benefits from revenue growth across both its segments as well as across all the product categories within its Cardiovascular unit.